Prostate Cancer Risk Among Men with Diabetes Mellitus (Spain)

Centro Español de Investigación Farmacoepidemiológica (CEIFE), Madrid, Spain.
Cancer Causes and Control (Impact Factor: 2.74). 12/2005; 16(9):1055-8. DOI: 10.1007/s10552-005-4705-5
Source: PubMed


Observational studies have associated diabetes with a decreased risk of prostate cancer. We aimed to evaluate this association using the General Practitioner Research Database in the UK.
Population based case-control study nested in a cohort.
We identified 2,183 incident cases of prostate cancer between January 1995 and December 2001. We found that diabetic patients had a decreased risk of prostate cancer (OR = 0.72; 95% CI: 0.59-0.87). This association was observed among treated diabetics (OR = 0.63; 95% CI: 0.50-0.80) but not among untreated diabetics (OR = 1.01; 95% CI: 0.73-1.40). Our results suggest that the observed reduced risk could be restricted to users of insulin or sulphonylureas.
Patients with diabetes have a decreased risk of prostate cancer. The role of antidiabetic treatment in this association warrants further research.

Download full-text


Available from: Luis Alberto Garcia-Rodriguez
  • Source
    • "We also observed higher risks of breast, bladder, and endometrium cancers in women, which is consistent with findings from previous studies [19]. A significant inverse association between diabetes and prostate cancer has been observed in men, which is also consistent with previous epidemiological studies [19,35-38], but inconsistent with those that show no associations [30-34,39]. At the other sites, we found a negative association for esophageal and laryngeal cancers in males, as well as for cervical and connective and other soft tissue cancers in females. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background This study aims to determine cancer risks among patients with type 2 diabetes through a follow-up study on a nationwide population-based cohort that included Taiwanese diabetic patients and general population in Taiwan as well as to estimate the population attributable fraction (PAF) of site-specific cancer risks that can be attributed to type 2 diabetes in Taiwanese population by using standardized incidence ratios (SIRs, 95% CI). Methods Subjects with type 2 diabetes consisted of 472,979 patients aged ≥20 years, whereas general population consisted of 9,411,249 individuals of the same age limit but are not diabetic. Subjects were identified from 1997 to 1998 and followed up until December 31, 2007 or until the first manifestation of any cancer. Results Cancer sites with increased risks in men, which were consistent with the main and sensitivity analyses, included pancreas (SIR = 1.62; 95% CI = 1.53 to 1.72), liver (1.61; 1.57 to 1.64), kidney (1.32; 1.25 to 1.40), oral (1.16, 1.12 to 1.21), and colorectal (1.19, 1.15 to 1.22). Cancer sites with increased risks in women included liver (1.55; 1.51 to 1.60), pancreas (1.44; 1.34 to 1.55), kidney (1.38; 1.30 to 1.46), endometrium (1.36; 1.26 to 1.47), bladder (1.19; 1.11 to 1.27), colorectal (1.16; 1.13 to 1.20), and breast (1.14; 1.09 to 1.18). Overall, PAFs were highest for liver cancer in men (4.0%) and women (3.7%), followed by pancreas (3.4%) and kidney (1.6%) cancers in men, and then for endometrium (1.8%) and kidney (1.8%) cancers in women. Conclusion Our data suggested that increased cancer risks are associated with type 2 diabetes.
    Full-text · Article · May 2014 · BMC Cancer
  • Source
    • "However, variables representing use of TZDs, sulfonylureas and biguanides were included regardless of their P-values. Because diabetes is associated with an increased incidence of breast and endometrial cancers and a reduced incidence of prostate cancers [2-4], we also performed separate multivariate analyses for men and women. Because the effects of TZDs on cancer might be mediated through pathways other than PPARγ, and therefore not be an effect of all TZDs, we also performed separate analyses for pioglitazone and rosiglitazone. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peroxisome proliferator-activated receptors (PPARs) have emerged as important drug targets for diabetes. Drugs that activate PPARgamma, such as the thiazolidinediones (TZDs), are widely used for treatment of Type 2 diabetes mellitus. PPARgamma signaling could also play an anti-neoplastic role in several in vitro models, although conflicting results are reported from in vivo models. The effects of TZDs on cancer risk in humans needs to be resolved as these drugs are prescribed for long periods of time in patients with diabetes. A total of 1003 subjects in community practice settings were interviewed at home at the time of enrolment into the Vermont Diabetes Information System, a clinical decision support program. Patients self-reported their personal and clinical characteristics, including any history of malignancy. Laboratory data were obtained directly from the clinical laboratory and current medications were obtained by direct observation of medication containers. We performed a cross-sectional analysis of the interviewed subjects to assess a possible association between cancer diagnosis and the use of TZDs. In a multivariate logistic regression model, a diagnosis of cancer was significantly associated with TZD use, even after correcting for potential confounders including other oral anti-diabetic agents (sulfonylureas and biguanides), age, glycosylated hemoglobin A1C, body mass index, cigarette smoking, high comorbidity, and number of prescription medications (odds ratio = 1.59, P = 0.04). This association was particularly strong among patients using rosiglitazone (OR = 1.89, P = 0.02), and among women (OR = 2.07, P = 0.01). These data suggest an association between TZD use and cancer in patients with diabetes. Further studies are required to determine if this association is causal.
    Full-text · Article · Feb 2007 · BMC Medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In der vorliegenden Arbeit wurde das Datenbanksystem CARE – Cancer Recording zur Tumordokumentation in der Mund-, Kiefer-, Gesichtschirurgie - entwickelt. Die Datenbank ermöglicht die Eingabe von prätherapeutischen und therapeutischen Daten, der Pathologie, Nachsorge und Abschlussdaten von Tumorpatienten, die an malignen Kopf-Hals-Tumoren erkrankt sind. Somit kann eine Verwaltung und Auswertung dieser Daten vorgenommen werden, um daraus Schlüsse für die klinische Forschung, die Qualitätssicherung sowie für krebsepidemiologische Forschungsaufgaben zu ziehen. Das Programm basiert auf dem relationalen Datenbankprogramm Microsoft Access und berücksichtigt auch den Aufbau der ADT-Bögen (Version III) mit dessen geforderten Angaben. Die gespeicherten Datenmengen sind somit auch kompatibel mit überregionalen Krebsregistern wie z.B. dem DÖSAK. Es wurde auf höchstmöglichen Bedienkomfort, größtmöglichen Ausschluss von Fehleingaben, einfachen Export von Daten in andere Programme und sofortige Auswertung und Abrufbarkeit von ausgewählten Statistiken geachtet. This dissertation presents the data base system CARE – Cancer Recording for tumour documentation in maxillofacial surgery. The data base allows to enter pre-therapeutic and therapeutic data, as well as data of pathology, aftercare and conclusion of tumour patients who are diseased with maligned tumours of the maxillofacial region. Thus, these data can be managed and analysed with the purpose of drawing conclusions for clinical research, quality control and tumour-epidemiological research. The program is based on the relational data base program Microsoft Access and takes into account the composition of the ADT-sheets (version III) and the information they require. The recorded amounts of data are therefore compatible with supra-regional tumour indices, e.g. the DÖSAK. Important points were to assure the highest possible ease of use, the greatest possible exclusion of erroneous entering of data, the easy export of data into other programs, instant analysis and the possibility to recall data from selected statistics.
    Preview · Article ·
Show more